Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden

Verhoef, T. I.UCL, Dept Appl Hlth Res, London, England; Univ Utrecht, Div Pharmacoepidemiol & Clin Pharmacol, Dept Pharmaceut Sci, Utrecht, Netherlands (författare)

We aimed to assess the cost-effectiveness of pharmacogenetic-guided dosing of warfarin in patients with atrial fibrillation (AF) in the United Kingdom and Sweden. Data from EU-PACT, a randomized controlled trial in newly diagnosed AF patients, were used to model the incremental costs per quality-adjusted life-year (QALY) gained by pharmacogenetic-guided warfarin dosing versus standard treatment over a lifetime horizon. Incremental lifetime costs were £26 and 382 Swedish kronor (SEK) and incremental QALYs were 0.0039 and 0.0015 in the United Kingdom and Sweden, respectively. The corresponding incremental cost-effectiveness ratios (ICERs) were £6 702 and 253 848 SEK per QALY gained. The ICER was below the willingness-to-pay threshold of £20 000 per QALY gained in 93% of the simulations in the United Kingdom and below 500 000 SEK in 67% of the simulations in Sweden. Our data suggest that pharmacogenetic-guided dosing of warfarin is a cost-effective strategy to improve outcomes of patients with AF treated with warfarin in the United Kingdom and in Sweden.

Redekop, W. K.Erasmus Univ, Inst Med Technol Assessment, Rotterdam, Netherlands (författare)
Langenskiöld, SophieUppsala universitet,Hälsoekonomi,Karolinska Inst, Dept Learning Informat Management & Eth, Stockholm, Sweden(Swepub:uu)sopla565 (författare)
Kamali, F.Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England (författare)
Wadelius, MiaUppsala universitet,Klinisk farmakogenomik och osteoporos,Science for Life Laboratory, SciLifeLab(Swepub:uu)miawadel (författare)
Burnside, G.Univ Liverpool, Inst Translat Med, Block A,Waterhouse Bldg,1-5 Brownlow St, Liverpool L69 3GL, Merseyside, England (författare)
Maitland-van der Zee, A-H.Univ Utrecht, Div Pharmacoepidemiol & Clin Pharmacol, Dept Pharmaceut Sci, Utrecht, Netherlands (författare)
Hughes, D. A.Bangor Univ, Ctr Hlth Econ & Med Evaluat, Bangor, North Wales, Wales (författare)
Pirmohamed, M.Univ Liverpool, Inst Translat Med, Block A,Waterhouse Bldg,1-5 Brownlow St, Liverpool L69 3GL, Merseyside, England (författare)
UCL, Dept Appl Hlth Res, London, England; Univ Utrecht, Div Pharmacoepidemiol & Clin Pharmacol, Dept Pharmaceut Sci, Utrecht, NetherlandsErasmus Univ, Inst Med Technol Assessment, Rotterdam, Netherlands (creator_code:org_t)

Ingår i:The Pharmacogenomics Journal: Springer Science and Business Media LLC16:5, s. 478-4841470-269X1473-1150

Av författaren/redakt...: Verhoef, T. I.; Redekop, W. K.; Langenskiöld, So ...; Kamali, F.; Wadelius, Mia; Burnside, G.; visa fler...; Maitland-van der ...; Hughes, D. A.; Pirmohamed, M.; visa färre...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Hälsovetenskap; och Hälso och sjukvå ...

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.